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A major goal of systems biology is the development
of models that accurately predict responses to
perturbation. Constructing such models requires
the collection of dense measurements of system
states, yet transformation of data into predictive
constructs remains a challenge. To begin to model
human immunity, we analyzed immune parameters
in depth both at baseline and in response to influ-
enza vaccination. Peripheral blood mononuclear
cell transcriptomes, serum titers, cell subpopulation
frequencies, and B cell responses were assessed in
63 individuals before and after vaccination and
were used to develop a systematic framework to
dissect inter- and intra-individual variation and build
predictive models of postvaccination antibody re-
sponses. Strikingly, independent of age and pre-
existing antibody titers, accurate models could
be constructed using pre-perturbation cell popula-
tions alone, which were validated using indepen-
dent baseline time points. Most of the parameters
contributing to prediction delineated temporally
stable baseline differences across individuals,
raising the prospect of immune monitoring before
intervention.INTRODUCTION
The development of accurate models that predict biological re-
sponses is one of the major goals of systems biology. Such
models have the potential to increase our understanding of path-
ophysiology and contribute to the development of improved
therapeutics (Kitano, 2002; Schadt, 2009). The human immune
system provides an excellent context for developing such ap-
proaches: many immune cells and molecular components are
readily accessible from blood, permitting collection of samples
from individuals across multiple time points, followed by in-
depth data generation and analyses (Davis, 2008; Pulendran
et al., 2010). Furthermore, it is increasingly clear that the immune
system and inflammation contribute not only to the pathogenesis
of autoimmune and infectious disease, but also to cancer, car-
diac disease, diabetes, obesity, neurodegeneration, and other
chronic illnesses (Germain and Schwartzberg, 2011). Thus, a
more comprehensive and quantitative understanding of how
immune responses are orchestrated, together with identification
of predictive parameters of effective versus damaging re-
sponses, could have implications for the prevention and treat-
ment of diverse diseases.
Building quantitative models often involves the application of
perturbations to the system and comprehensive measurements
of the initial and resulting states (Chuang et al., 2010). Although
advances in high-throughput technologies have made such
measurements more routine, utilization of appropriate and
ethical perturbations in humans is often a challenge. Here, theCell 157, 499–513, April 10, 2014 ª2014 Elsevier Inc. 499
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Figure 1. Study Design
Study design indicating blood collections and assays performed. Each subject
was vaccinated with the seasonal and pandemic H1N1 influenza vaccines
right after the day 0 blood draw.immune system again offers an advantage, as it is amenable to
experimental manipulation. The inactivated influenza vaccine,
in particular, is used routinely in healthy and ill populations (Fiore
et al., 2009) and provides an attractive perturbation for global
data collection and systematic modeling. Upon vaccination,
the immune system responds with coordinated changes that
reflect the activation and interaction of distinct cell populations
and pathways, culminating in the generation of short-lived
plasma cells and the formation of germinal centers, from which
high-affinity long-lived antibody-producing plasma and memory
B cells derive (Pulendran and Ahmed, 2011). By one week post-
immunization, a strong but transient plasmablast response can
be detected in the blood (Cox et al., 1994; Pulendran et al.,
2010), accompanied by increased antibodies in the serum (de
Jong et al., 2003). Accordingly, transcriptional profiling of periph-
eral blood mononuclear cells (PBMCs) revealed substantial
changes on days 1, 3, and 7 postvaccination, reflecting both
early innate immune activation and day 7 plasmablast responses
(Bucasas et al., 2011; Nakaya et al., 2011; Obermoser et al.,
2013). Thus, influenza vaccination provides an excellent model
of coordinated immune activity involving innate and adaptive
responses.
While perturbation analysis is a cornerstone of systems
biology, another critical factor for building models in humans is
natural population variation. Differences in genetics and environ-
ment result in substantial diversity in molecular and cellular
states among individuals before and after perturbation. Through
correlation analysis, heterogeneity among individuals provides
raw ingredients to infer functional relationships among system
components—links that cannot be drawn if the parameters
analyzed have insufficient diversity in a population. For example,
intersubject variation in PBMCgene expression after vaccination
has helped to identify postvaccination transcript correlates for
antibody responses to yellow fever or influenza vaccination
(Gaucher et al., 2008; Nakaya et al., 2011; Querec et al., 2009).
However, with the exception of age, how intersubject differences
at baseline contribute to outcome has not been well examined. A
better characterization of immune variation in healthy individuals
is critical not only for the identification of correlates and model
building, but also for biomarker development, the definition
and characterization of pathological states, and eventually,
personalized medicine.500 Cell 157, 499–513, April 10, 2014 ª2014 Elsevier Inc.Here, we present a computational framework that utilizes
vaccination and multiplexed measurements (gene expression,
high density analyses of cell populations, and cellular and
serological responses) to quantify baseline and response
heterogeneity in a cohort of individuals and systematically
identify correlates, build predictive models of vaccination
response quality, and infer functional connectivities in the
immune system. Using antibody responses as an exemplar
endpoint, our analyses confirmed previously reported post-
vaccination transcriptome correlates (Gaucher et al., 2008;
Nakaya et al., 2011; Querec et al., 2009). Importantly, after
accounting for the influence of pre-existing serology, age,
ancestry, and gender, we have successfully constructed
predictive models and have identified correlates of antibody
responses based on prevaccination parameters alone. The
robustness and translational potential of these findings is
emphasized by our demonstration that the parameters playing
essential roles in accurate prediction were cell subsets with
temporally stable baseline values within individuals, raising
the prospect of predicting the quality of immune responses
in the clinic. The data and analytic framework presented pro-
vide a potential resource for studying human immunity in health
and disease.
RESULTS
In-Depth Analysis of Human Immune Status before and
after Vaccination
As a first step toward developing a systems-level understanding
of human immunity, we generated a database of immunological
measurements using samples drawn from healthy volunteers
before and after administration of the 2009 seasonal and
pandemic H1N1 (pH1N1) vaccines (Fiore et al., 2009; Table S1
available online and Figure 1). To facilitate the evaluation of
intra-individual variation, two baseline blood samples were ob-
tained: one a week before and the other immediately prior to
vaccination. Responses were evaluated on days 1, 7, and 70
postvaccination to examine innate, adaptive, and long-term re-
sponses, respectively (Figure 1). Purified PBMCs and sera
were frozen to allow subsequent assessments to be performed
at the same time for a given individual, thereby minimizing batch
effects. For the present study, assays included antibody-forming
cell responses, influenza-specific serum neutralization titers,
multiple 15 color flow cytometric analyses (examining 126 cell
subpopulations), and transcriptome analyses using microarrays
(Figures 1 and S1A andS1B). Analyseswere performed on the 63
subjects from whom we were able to obtain samples at all
scheduled time points.
Substantial Immune Baseline Variations in Healthy
Subjects
We first examined baseline variation in immune parameters. As
expected for subjects from the general population, we found a
wide range of baseline titers to the seasonal vaccine, with corre-
sponding large variations in vaccine-specific memory B cell
numbers (Figure S2A) (Sasaki et al., 2008). In contrast, most of
the cohort was naive for the pH1N1 virus based on titers,
despite some potential cross-reactive memory B cell responses,
consistent with previous observations (Hancock et al., 2009; Li
et al., 2012).
Examination of 126 PBMC subsets (Biancotto et al., 2011)
(Figure S1B and Table S2) revealed a wide range of frequencies
formany cell populations on day 0 (Figure S2B). Cell subsets with
the highest variability among individuals were typically charac-
terized by expression of activation markers or cytokines, likely
reflecting activation of cells within a broadly defined parent
population. To exclude experimental variability as the primary
source of variation, we analyzed multiple aliquots of a control
frozen PBMC sample along with an independent group of sam-
ples over a 2-month period. We found that technical variability
was minimal (average control sample replication R2 = 0.99;
Figure S1B).
Aside from experimental noise, variation can be attributed to
the combined effects of baseline differences across individuals
(intersubject baseline variation) and temporal changes around
the baseline within subjects (intrasubject variation). We took
advantage of our multiple baseline measurements (days 7, 0,
and 70) to assess the relative contribution of these two types
of variation for each cell subset. Day70was used as an additional
baseline because we did not observe substantial postvaccina-
tion changes except for influenza-specific antibody titers and B
cell memory responses (Figure 2A; Experimental Procedures).
Among populations with high overall variability, many B cell sub-
sets showed low within-subject variability (and therefore high
temporal stability) over a period ofmore than 2months (indicated
in dark gray in Figure 2A).
Transcript abundance for day 0 PBMCs also showed substan-
tial variation (Figure 2B), likely reflecting, in part, the different
proportions of cell subsets among subjects. To better quantify
this variation in a functional context, we developed an approach
to summarize ‘‘pathway activity’’ for each subject based on
whether a substantial number of genes in a given annotated
pathway or function were expressed at different levels in the
PBMC of the individual relative to the cohort average (see Exper-
imental Procedures). In addition to innate and adaptive immune
pathways (Figures S2C and 2C), somemetabolic pathways were
also highly variable (Figure S2C), perhaps reflecting changes in
metabolic profiles that occur in immune cells upon activation
and differentiation (Gerriets and Rathmell, 2012). Assessment
of inter- versus intrasubject variation demonstrated diverse pat-
terns, with subject-to-subject baseline differences (blue bars)
contributing substantially to the observed variability of many
genes and pathways (Figures 2B and 2C).
Coherent Changes in Immune Parameters
Postvaccination
We next evaluated whether we could detect coherent changes
(i.e., consistent across subjects) following vaccination. As ex-
pected, we observed strong but highly variable increases in influ-
enza vaccine-specific IgG+ antibody-secreting cells on day 7
(Figure 3A). As previously reported (Bucasas et al., 2011; Nakaya
et al., 2011; Obermoser et al., 2013), we also found coherent
changes in gene expression, with largely nonoverlapping signa-
tures on days 1 and 7 (Figures 3B and 3C). Overall, day 1
responses included pathways reflecting innate immune-cell
activation, including interferon-related genes, as observed byothers (Bucasas et al., 2011; Nakaya et al., 2011; Obermoser
et al., 2013) (Figure 3C and Table S3). By day 7, adaptive path-
ways were more predominant, including those strongly associ-
ated with plasmablasts, such as ‘‘endoplasmic reticulum (ER)
stress’’ and ‘‘N-glycan biosynthesis’’ (see below) (Gass et al.,
2004; Iwakoshi et al., 2003). Nonetheless, transcript changes
associated with adaptive responses were also observed on
day 1, including ‘‘B cell receptor signaling.’’
We were particularly interested in evaluating changes in the
frequency of cell subsets, the majority of which have not been
examined in the context of vaccination. As with the transcrip-
tome, changes in subset frequencies on days 1 and 7 were
largely nonoverlapping (Figure 3D). Again, day 1 changes re-
flected activation of innate immune cells, including CD40+ and
CD86+ monocytes (ID65 and ID67) and IFNa+ plasmacytoid
DCs (ID78), populations that have been linked to vaccination
efficacy and responses to influenza (Fonteneau et al., 2003;
van Duin et al., 2007). However, we also observed changes in
adaptive cell populations, particularly those reflecting activation
of CD8+ and CD4+ T cells, as well as both naive and memory B
cells (Kaminski et al., 2012). Day 7 responses primarily reflected
changes in adaptive cell populations, including plasmablasts
(ID87), as expected, but also in a relatedCD20+B subset that ex-
pressed CD27 and CD38 (ID96; Figure S3), as well as activated
T cell populations. Thus, despite substantial baseline differences
among subjects, there were clear coherent changes in cell pop-
ulations and gene expression postvaccination, with days 1 and 7
involving distinct cell types and genes.
Antibody Titer and Cellular Responses Depend on
Prevaccination Serological State
A major question in understanding human immunity is the extent
to which responses to a perturbation are affected by pre-existing
immune status. To address this question, we first assessed the
effects of day 0 serology andmemory B cell status on outcomes.
To evaluate titer responses, we adopted the ‘‘fold-change from
baseline’’ metric used by the FDA andWorld Health Organization
for the evaluation of vaccine efficacy (Figures 4A and S4A).
Because the day 70 over day 0 fold change in titer correlated
with both the day 7 fold change in titer and effector B cell re-
sponses and thus reflected both short- and long-term responses
(Figures S4B and S4C), we used day 70 titer responses as the
endpoint for subsequent analyses. Interestingly, subjects with
higher initial titers tended to have lower fold changes. Though
not intuitively obvious, inverse correlations have been observed
in other influenza vaccination studies (Bucasas et al., 2011; Fur-
man et al., 2013; Sasaki et al., 2008).
Next, we clustered subjects using a combination of six base-
line parameters: the four normalized baseline titers to the viruses
targeted by the vaccines and the fractions of memory IgG+ B
cells specific for the seasonal and pH1N1 vaccines (Experi-
mental Procedures). Unsupervised clustering followed by
robustness analysis (Experimental Procedures) revealed two
separable groups containing 33 and 26 subjects. Group 1 indi-
viduals were generally low for all six parameters, whereas
group 2 had mostly higher values though less uniformly so for
pH1N1 titers (Figure 4B). Analyses of postvaccination transcript
changes revealed no significant differences between the twoCell 157, 499–513, April 10, 2014 ª2014 Elsevier Inc. 501
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Figure 2. Inter- and Intrasubject Variation at Baseline
(A) Variation in cell population frequencies at baseline. The length of the bar denotes observed sum of squares (R2). Blue and gray designate R2 attributed to inter-
and intrasubject variation, respectively.
(B) Variation in gene expression at baseline. Hierarchical-clustered heatmap of the 500 most variable genes and the relative proportion of inter- and intrasubject
variation (Experimental Procedures).
(C) Clustered heatmaps of genes from two variable immune relevant pathways showing distinct patterns of expression heterogeneity across subjects (see
Figure S2C and Experimental Procedures).groups. However, the more naive group exhibited significantly
greater increases in plasmablasts (ID87) and seasonal vaccine-
specific ELISpot responses on day 7 (Figure 4C). Thus, both
the plasmablast response on day 7 and the mean fold change
in titers on day 70 were inversely correlated with initial titers.
Systematic Identification of Pre- and Postvaccination
Predictors and Correlates
Wenext developed a systematic framework to take advantage of
intersubject baseline and response variations to build predictive
models of antibody responses. Our approach involved delinea-502 Cell 157, 499–513, April 10, 2014 ª2014 Elsevier Inc.tion of the impact of intrinsic (e.g., age and gender), baseline,
and response variables on outcome (Figure 5A). Given that
most studies have focused primarily on linking postvaccination
parameters to titers, we were especially interested in whether
baseline parameters correlated with and could potentially pre-
dict outcome independent of age, gender, and pre-existing anti-
body titers.
Defining Titer Response Endpoints
To account for the strong influence of baseline titer on day 70 re-
sponses, we devised two endpoint metrics. The first, maximum
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fold change (MFC), was defined as the maximum of the day 70
over day 0 fold change across all viral titers, based on normalized
values (Experimental Procedures). The second, adjusted MFC
(adjMFC), removed the nonlinear correlation between MFC and
day 0 titers by first dividing the cohort into groups of subjects
with similar day 0 titers and then adjusting the response within
each group so that they were normalized and thus comparable
(see Experimental Procedures and related approaches [Bucasas
et al., 2011; Nauta, 2011]). Finally, for each metric, we defined
‘‘high’’ and ‘‘low’’ responders as subjects ranked above or below
the top or bottom 20th percentile mark of the metric, respec-
tively. We modeled the maximum response (Nakaya et al.,
2011) because none of the cell population and gene expression
parameters that we assessed targeted specific antigens. Thus,
our goal was to determine whether models could be built to pre-
dict robust responses to at least one of the vaccine antigens.
Our analyses suggested that baseline titer alone should be a
predictor of antibody responses postvaccination. However, re-
sponses were still highly variable within groups of individuals
with similar baseline titers (Figures 4A and S4A). Thus, this vari-
ation (captured by adjMFC) could be utilized to determine base-
line titer-independent correlates and predictive models. Though
we were mainly interested in adjMFC, we also analyzed MFC to
assess the effects of day 0 titers on prediction and associated
predictive parameters.
Contributions of Intrinsic Factors
We first assessed the effects of intrinsic factors, including age,
gender, and self-reported ancestry (Figure 5A), by using
ANOVA analysis on all variables simultaneously. Consistent
with previous data (Furman et al., 2013; Goodwin et al., 2006;
Gross et al., 1995), age was the only correlate for both metrics
(Figure 5B). As expected, initial titers were significantly corre-
lated with MFC (Figure 5B), but not with adjMFC, for which
more than 80% of the variance remained unexplained.
MethodOverview for the Identification of Predictors and
Correlates
We next conducted two types of analyses—predictive modeling
and robust correlate identification—to assess whether any base-
line or postvaccination parameters were associated with re-
sponses. Predictive modeling analyses pooled the high and low
responders in our cohort and randomly divided them into
nonoverlapping training and testing sets containing 75% and
25% of the subjects, respectively; the former was used for build-
ing models whose predictive performance was then evaluated in
the unseen testing set (Experimental Procedures). Analyseswere
repeated 5,000 times using different randomly generated sets toFigure 3. Postvaccination Changes in Serologic, Cellular, and Transcr
(A) Increased antigen-specific antibody secreting cells on day 7 following vaccin
(B) Heatmap of genes from days7, 1, 7, and 70 that changed significantly comp
day 0 is indicated by color). Genes with similar patterns of change were grouped
(C) Coherently changed genes in the clusters from (B). (Right) Representative imm
(Experimental Procedures). Genes found to be predictive of or correlated with res
marked in blue.
(D) Coherently changed cell populations on days 1 and 7 postvaccination (FDR
populations considered ‘‘innate’’ and ‘‘adaptive,’’ respectively.
504 Cell 157, 499–513, April 10, 2014 ª2014 Elsevier Inc.evaluate the robustness of themodel constructionmethod and to
identify parameters that consistently contributed to prediction.
When prediction was not possible, we also assessed whether
we could identify parameters that consistently correlated with
the response endpoints when different random subsets of sub-
jectswere used in the analysis (Experimental Procedures)—while
an endpoint may have such robust correlates, these may be
insufficient for reliable, quantitative prediction.
The first step for training predictive models involved selecting
the top k parameters based on the parameters’ strength of cor-
relation with the endpoint in the training set; we tested multiple
values of k (see below). Our criterion for assessing robust pre-
diction was to determine whether the area under the receiver
operator characteristic curve (AUC) was above 0.5 in at least
75% of the 5,000 iterations (0.5 is the AUC level expected by
chance). To reveal which parameters contributed to prediction,
we identified those that were: (1) consistently ranked in the top
k and therefore selected for model construction in a large num-
ber of iterations (% selected) and (2) weighted highly by the
model in making its predictions (median weight) (Experimental
Procedures).
Identification of Postvaccination Predictors and Robust
Correlates
Given previous findings of postvaccination transcript correlates
with antibody responses (Nakaya et al., 2011), we first examined
data from days 1 and 7. To ensure that correlates were indepen-
dent of intrinsic factors, we removed age, gender, and race
effects from both cell population and gene expression data
sets via linear regression (Experimental Procedures). Though
models built using either gene expression or cell populations
from day 1 were not predictive, interferon signaling correlated
robustly with MFC (Figure 5C). Coherent changes in interferon-
associated transcripts have been detected on days 1 and 7 in
our and other related studies (Bucasas et al., 2011; Gaucher
et al., 2008; Nakaya et al., 2011; Obermoser et al., 2013; Querec
et al., 2009). In contrast, highly predictive models could be built
using day 7 cell population or gene expression data for both
adjMFC and MFC (Figures 5D and 5F). Consistent with previous
findings (Nakaya et al., 2011), MFC could be predicted using as
few as two or five genes, though more were required for adjMFC
(Figure 5F). Notably, robustly correlated (Figure 5C) and predic-
tive genes (Table S4) were enriched for ER stress, N-glycan
biosynthesis, and cell-cycle pathways, whose gene members
correlated strongly with plasmablast frequencies (see below).
Accordingly, plasmablasts (ID87) and the overlapping CD20+
subpopulation (ID96) were the dominant cellular contributors
(Figure 5E) (Withers et al., 2007).iptomic Parameters
ation measured by ELISpot.
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(A) Relationship between initial and fold change (day 70/day 0) in titer for A/Uruguay after vaccination (see Figure S4 for other viruses). Histogram at left shows
distribution of the titer responses.
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for the low (1) and high (2) initial titer groups from (B).
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Identification of Prevaccination Predictors and
Correlates
We next asked whether predictive models could be built using
baseline (day 0) parameters alone. Again, we removed age,
gender, and ancestry from cell population and gene expression
data to ensure that models and correlates that we identified were
independent of these factors (Experimental Procedures). Neither
day 0 gene expression nor pathway activity (defined in Fig-
ure S2C) alone was predictive of either endpoint, though a
number of robustly correlated genes and pathways could be
identified (Figure 6A). Notably, genes associated with pattern
recognition and interferon signaling robustly correlated to MFC
but less so to adjMFC.
We then built and tested models for MFC and adjMFC using:
(1) the frequency of 126 cell populations or (2) both the cell
population frequencies and the activity score of 183 annotated
pathways (Figure S2C). Cell frequency and transcript data
were integrated using the pathway activity score because the
numbers of pathways and cell populations were comparable,
whereas the large number of genes could overwhelm signal
from cell populations. Of note, predictive models could be
built by using cell populations alone (Figure 6B); integrating
pathway/transcript with cell population data performed substan-
tially worse (best median AUC was 0.6 versus 0.78 using cell
populations alone). Thus, day 0 cell frequencies alone provided
the essential information for prediction.
We next identified cell populations that contributed most to
prediction. Twelve cell populations were identified for adjMFC,
including memory, naı¨ve, and transitional B cells; CD4 effector
memory T cells; IFNa+myeloid dendritic cells (mDC); and several
activated T cell populations (Figure 6C and Experimental Proce-
dures). Several of the B cell populations were CD38+, including
CD20+IgD-CD27+CD38+ B cells (ID96), as well as transitional
(ID91) and naive (ID108) populations and an IgD+CD27+memory
population (ID103) that has been linked to early production of IgM
(Shi et al., 2003). Only some of these populations—primarily the
T cell subsets—contributed to the prediction of MFC (Figure 6C).
Thus, by accounting for baseline serology using adjMFC, we un-
covered additional baseline predictors.
Temporal Stability of Predictive Cell Populations
To evaluate the temporal stability of the day 0 predictive cell pop-
ulations, we examined their intra- versus intersubject variation
over time (Figure 2A). Except for ID105 (CD86+IgD+ memory BFigure 5. Predictive Modeling of Antibody Response and Identification
(A) Conceptual framework for analyzing contributors to titer response variation
variation in baseline immune statuses (day 0, marked in blue) and postvaccinati
could, in turn, contribute to response variation, and all sources of variation could t
were analyzed following the ‘‘flow’’ of time. (Right) The contributions of intrinsic va
and response (days 1 and 7) parameters, which were then analyzed in a similar s
(B) ANOVAmodeling of day 70 titer response using age, gender, ethnicity, and bas
p values are shown for MFC and adjMFC.
(C) Robust transcriptomic correlates from days 1 and 7 postvaccination (shown as
100 random trials) that apathwaywasenriched (p<0.05) is shown.Pathways thatw
(D) Prediction performance for MFC and adjMFC is shown for models built using
imental Procedures).
(E) Day 7 predictive cell populations (see Results and Experimental Procedures
included in themodel is shown. Median normalized weights of each population are
between the cell population and the titer endpoint.cells), all of the B cell and some of the CD4+ T cell (including
effector memory) predictive populations were remarkably stable
within individuals over aperiodofmore than2months (Figure 6D).
Among these were B cell subsets that also exhibited some of the
highest intersubject variation among all of the cell populations
that we measured (e.g., ID103 and 91; Figure 2A), suggesting
that these may be robust baseline markers for delineating inter-
subject differences. These stable B cell populations (ID91, 96,
103, 108) were all CD38+ and contributed to the prediction of
adjMFC, but not MFC. Examining the predictive cell populations’
temporal profile further confirmed their stability and ability to
separate the high and low responders (Figures 6E, 6F, and S5).
This was true even for ID96, which increased coherently across
subjects at day 7 postvaccination and returned to lower levels
by day 70. Together, these results suggest that many of the pre-
dictive markers that we uncovered reflected stable individual
differences in baseline immune states that correlated with the
capacity for robust responses to influenza vaccination.
Because some of the predictive populations were less tempo-
rally stable and thusmay indicate transient events (e.g., an infec-
tion), we next assessed whether predictive models could be built
using only the 56 most stable populations (those above the 80%
stability mark; Figure 6D) as inputs to our 5,000 iteration cross-
validation assessment. Even using a smaller k of 10 (versus
30 previously), adjMFC could be robustly predicted (median
AUC = 0.78; Figure 6G). As expected, the populations contrib-
uting most to adjMFC prediction were the same stable ones
identified above. Thus, the less stable populations were not
essential for adjMFC prediction. In contrast, use of the stable
cell populations decreased the predictive performance for
MFC, which remained flat for all values of k. However, if the sta-
ble populations above the 80% mark in Figure 6D were omitted
instead, performance remained high for MFC (median AUC =
0.83 for k = 10) but dropped substantially for adjMFC (median
AUC = 0.56 for k = 10). Thus, the more transient signals provided
the bulk of the predictive power for MFC, whereas that for
adjMFC came from temporally stable parameters that may
have captured the unique immune status of individuals.
We further evaluated the robustness of our results by building
models using the entire cohort’s day 0 cell population data as the
training set (k = 2, 5, 10, or 30) and then assessing whether these
models could predict adjMFC using independent measurements
from other baseline time points (day 7 or the more temporally
removed day 70). Highly accurate prediction could still beof Correlates
following vaccination. Variation in intrinsic factors (purple) could contribute to
on responses (days 1 and 7, marked in green and orange). Baseline variation
ogether contribute to variation in titer responses. Contributions to titer variation
riables were first analyzed, and their effects were removed from baseline (day 0)
tep-wise manner (Experimental Procedures).
eline titers. Fraction of variance explained by each variable and the associated
pathway enrichments) (Experimental Procedures). The percentage of times (in
ere significant inmore than80%of the trials in at least one timepoint are shown.
different number of top cell populations (D) and genes (F) from day 7 (Exper-
). The percentage of times (in 5,000 random trials) that a cell population was
shown on the right. The sign of the weight indicates the direction of correlation
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made for all k’s, e.g., AUC= 0.91 and AUC= 0.86 for days7 and
70 using k = 10, respectively. Thus, the predictive signals were
remarkably stable over time.
Transcriptomic Signature of the Predictive Cell
Populations
To obtain functional insight into the predictors, we took advan-
tage of our simultaneous assessments of cell population fre-
quencies and the PBMC transcriptome to identify transcripts
and associated pathways whose abundance correlated with
the frequency of predictive cell subsets (Experimental Proce-
dures). As expected, the two predictive and coherently changing
cell populations from day 7 (ID87 and ID96) were linked to
known antigen-secreting cell/B cell/plasmablast-specific genes,
including Ig chains, XBP1 and IRF4, aswell as plasmablast-asso-
ciated pathways such as ER stress (Figures 7B and 7D). These
populations were also associated with N-glycan biosynthesis,
consistent with the highly glycosylated state of immunoglobulins
and the requirement for proper glycosylation for plasma cell
development (Tulp et al., 1986). Many plasmablast-correlated
genes were also ones that changed on day 7 (Figures 3B, 3C,
and 7B [marked in purple and orange]) and included genes found
to be predictive of or correlated with response titers in previous
studies (e.g., TNFRSF17) (Gaucher et al., 2008; Nakaya et al.,
2011; Querec et al., 2009). Thus, our analyses suggest that the
day 7 coherent and predictive signatures in our as well as previ-
ous studies were likely drawn from a tight coupling between titer
response and the degree of plasmablast expansion.
Our analyses also revealed that day 0 predictive populations
were associated with distinct transcriptomic signatures (Figures
7A and 7C). Several mitochondria-related pathways were posi-
tively associated with ID108 (CD38+ naive B cells) and ID91
(CD38hi transitional B cells), perhaps reflecting changes in bioen-
ergetic states associated with B cell development and activation.
ID36 (effector memory CD4+ T cells) and ID50 (perforin+ CD8+
cells) also shared signatures, suggestive of common features of
activation. Of note, several innate pathways (PRR signaling,
TREM1 signaling, and interferon-related genes) were positively
linked to IL22+ and IL2+ CD4+ T cells (ID25 and ID26) and were
negatively linked to ID36and ID50. Theassociationof innatepath-
ways with these adaptive subsets before vaccination suggests
that activationof thesepathways in theseor other interactingcells
may play important roles in determining response quality. Inter-
estingly, ID96, a day0predictiveBcell population that also coher-
ently increased on day 7 (Figures 3D and 6F), showed largely
distinct signatures on days 0 and 7 (Figures 7A–7D), suggesting
differences in the cell population defined by those markers or
distinct functional interactions with other cell populations post-
vaccination. Thus, by linking intersubject variation in geneexpres-Figure 6. Day 0 Predictors and Correlates
(A) Robust correlates between day 0 gene expression and response titers (see F
(B) Prediction performance using day 0 populations (as in Figure 5D).
(C) Day 0 predictive cell populations analyzed as in Figure 5E.
(D) Scatter plot of intrasubject stability (y) versus inter-subject variance (x) (see M
populations) and yellow (less stable).
(E and F) Temporal profiles of two stable predictive cell populations for high (o
correspond to samples with low viability.
(G) Predictive performance for day 0 using only the temporally stable populationsion to cell subset frequencies, our approach reveals potential
connections among components of the immune system.
DISCUSSION
Using influenza vaccination as a model perturbation, we have
gone beyond post hoc prediction and developed a framework
that transformsmultimodal data sets and natural population vari-
ation into predictive models that, unexpectedly, predicted sero-
logic responses to influenza vaccination in our cohort usingbase-
linePBMCsubpopulation frequencies alone, independent of age,
gender, initial serology, and the specificity of the cell populations
for vaccine antigens. Notably, the essential cell subsets contrib-
uting to prediction were among the most stable within subjects
over a time span of more than 70 days. Some of these also had
the highest intersubject variation and thus were likely predictive
because they delineated distinct baseline immune states among
individuals. Our findings raise the possibility of using such mea-
sures as biomarkers of immune response potential in the clinic.
Despite substantial intersubject differences at baseline, we de-
tected coherent changes in hundreds of transcripts postvaccina-
tion, as seen in recent vaccine studies (Bucasas et al., 2011;
Gaucher et al., 2008; Nakaya et al., 2011; Querec et al., 2009).
However, we also detected changes in the frequencies of cell
populations, many of which have not been examined in the
context of vaccination. Some of these changes reflect expected
biology, with innate immune activation early and adaptive
changespredominatingby1weekpostvaccination.Nonetheless,
themagnitude of responseswas intimately linked to the prevacci-
nation status of the individual, with lower initial titers being asso-
ciated with larger fold increases in serum titers and plasmablast
frequencies postvaccination. Although seemingly counterintui-
tive, such inverse correlations may reflect the current use of fold
change to measure vaccine responses, differences in response
timing (Henn et al., 2013), or inhibitory responses in pre-immune
subjects (He et al., 2008). Thus, initial serology is an important
yet potentially confounding variable that should be considered
when exploring correlates and building predictive models.
A key question is whether some of our predictors captured the
memory or activation status of the system due to prior exposure
or whether they are indicative of the immune system’s general
propensity to respond. For example, the overall immune
‘‘threshold’’ for mounting a response may be determined by ge-
netics and environmental factors such as the microbiota,
contemporaneous stimulations by prevalent viruses such as
CMV and EBV, or heterologous immunity due to degeneracy in
T cell recognition (Mu¨nz et al., 2009; Welsh and Selin, 2002).
Although it is possible that our observations were specific to
the particular season or cohort, several lines of evidence suggestigure 5C).
ethods). Predictive populations from (C) are highlighted in blue (more stable
range) and low (green) responders (based on adjMFC). Missing data points
s (those above the 80% mark in Figure 6D).
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that they have broader implications. First, the overall postvacci-
nation responses of our cohort were consistent with those
observed in other influenza vaccination cohorts from different
seasons (Bucasas et al., 2011; Furman et al., 2013; Nakaya
et al., 2011; Obermoser et al., 2013). Second, validation using
independent measurements from other baseline time points
(days7 and 70) suggests that the essential predictive cell pop-
ulations reflect stable baseline immune states as opposed to
acute events. Indeed, initial analyses of four of our predictive B
cell populations in healthy individuals from independent vaccine
cohorts across multiple seasons (Obermoser et al., 2013) pro-
vides further support for their temporal stability (data not shown).
Moreover, though the less stable predictive subsets (e.g., IFNa+
mDC [ID75] and CD86+IgD+memory B cells [ID105]) may reflect
temporary environmental effects, removing them from our data
only affected prediction of the initial titer-dependent endpoint
(MFC), but not the baseline serology-independent adjMFC. Sup-
porting the idea that B cell subsets can be useful response
predictors, a correlation between prevaccination levels of
class-switched memory B cells and serological responses to
vaccination has been recently shown (Frasca et al., 2012).
Another recent study has reported genetic determinants of im-
mune cell population frequencies in humans (Orru` et al., 2013).
Although B cell subset frequencies were not examined, it will
be of interest to assess whether genetics regulates the fre-
quencies of our temporally stable, predictive populations.
Byassociating changes ingeneexpressionwith changes in cell
population frequencies, we have started to explore the nature of
transcriptomic changes following vaccination. Changes in tran-
script abundance in PBMCs can originate from a combination
of alterations in gene expressionwithin individual cell populations
and changes in cell population frequencies. Others have started
to address these issues by sorting cell subsets followed by
expressionprofiling, by correlating expression changes to known
patterns of expression in major immune cell populations, or by
computational deconvolution to infer cell-population-specific
changes (Brandes et al., 2013; Nakaya et al., 2011; Shen-Orr
et al., 2010). Here, we also found that changes in some cells
were accompanied by transcript changes in the related cell pop-
ulations. Tight correlations between plasmablast frequencies on
day 7 and plasma cell-associated genes, such as immunoglobu-
lins, ER stress, cell cycle, and N-glycan biosynthesis pathway
genes, were involved. These plasmablast-correlated genes also
included many that were previously associated with postvacci-
nation response and predictive signatures (Nakaya et al., 2011;
Querec et al., 2009). Thus, our results suggest that many of these
transcriptomic changescanbeaccounted forby changes inplas-
mablast frequencies on day 7. Our observation that increases in
plasmablasts were more prominent in subjects with low baseline
titers, along with our integration of cell population, gene expres-
sion, and baseline immune status data, reveal that a sizableFigure 7. Gene Expression and Pathway Enrichment Signatures of Pre
Genes significantly correlated with predictive populations from (A) day 0 and (B) d
denoting the clusters from Figure 3B. Genes found to be predictive of or correlate
2011) are marked in blue. Analyses were performed separately for positively and
significantly correlated with at least one population are shown (FDR < 0.01). Pathw
cell populations (from Figure 6C).component of the day 7 predictive transcriptome signature for
MFC is likely derived from intersubject differences in prevaccina-
tion titers.
Unlike day 7 models, our baseline predictive models could
only be built using cell population frequencies, suggesting that
transcriptomic measurements of PBMCs were insufficiently sen-
sitive to capture intersubject differences derived from the day 0
predictive populations, in contrast to the highly transcriptionally
active plasmablasts. Whether expression data obtained from a
simpler transcript pool, such as sorted B cell populations, pro-
vides better predictive power remains an important question.
Correlating frequencies of cell populations with gene expression
can also potentially reveal the internal state of that cell subset as
well as that of other cell populations. Though most of our base-
line predictive populations are adaptive, they are strongly corre-
lated to genes and pathways with innate functions, some of
which may reflect the (activation) states of functionally interact-
ing cell populations. It will therefore be of interest to evaluate
immune-activation differences (e.g., responses of PBMCs to
TLR ligands) in high versus low responders to vaccination.
Even on day 7, when the overlapping populations ID87 and
ID96 were significantly correlated to largely the same genes
and pathways, ID96 exhibited a stronger inverse association
with several innate signaling pathways. These connections sug-
gest distinct features for the CD20+ and CD20 populations of
IgD-CD27+CD38+ B cells (Clutterbuck et al., 2006). Our results
highlight the importance of evaluating and integrating multiple
data sets for understanding human immune function.
Our data and analyses also serve as a potential resource for
characterizing normal human immunevariationsand their implica-
tions for health and disease. One important goal of this study was
to begin the building and analysis of the ‘‘normal human
immunome’’ that characterizes the status of the apparently
healthy immune systemmore broadly and fully than traditional as-
sessments for future mining and reference. Such information
would include clinical and family history, detailed cellular and
molecular measurements of immune status, andmicrobiome sta-
tus, as well as genome-wide genotypic information. Through the
quantification of inter- as well as intraindividual variations, such
a resource can provide essential baseline and comparative data
for analyses of immune system behavior after perturbation and,
through computational analyses, for de novo discovery of func-
tional connections amongmolecular, cellular, and physiologic pa-
rameters of the human immune system in health or disease.
Our study highlights the importance of untangling correlation
structures to identify the potential ‘‘root’’ correlates of responses
as opposed to ‘‘passengers.’’ We have specifically shown that
the strong effects of initial serology on titer outcome need to
be properly modeled in order to identify whether and which
baseline and response parameters contribute most to outcome.
This may be particularly important in the context of influenzadictive Cell Populations
ay 7. In (B), coherently changing genes from Figure 3 are highlighted by color,
d with response titers in a previous influenza vaccination study (Nakaya et al.,
negatively correlated genes (in red and blue scales, respectively). Only genes
ay enrichment analyses of gene correlates of (C) day 0 and (D) day 7 predictive
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vaccination, in which partial immunity is highly prevalent. Our
adjMFC metric helped to reveal a number of temporally stable
correlates not associated with MFC and thus may be useful in
similar vaccine studies. One major constraint limiting predictive
model construction and the discovery of novel functional rela-
tionships among parameters in a study like ours is statistical
power, partially because the number of subjects, particularly
the extreme responders, is far less than the thousands of
parameters measured and the need to correct for multiple hy-
pothesis testing. Meta-analyses across multiple studies will start
to mitigate this issue but require the coordinated development
and sharing of experimental and computational approaches in
the research community to address issues ranging from control-
ling batch effects and standardizing quality control metrics to
constructing predictive models. Achieving such integrated ap-
proaches across research centers will provide a major step for-
ward in using computational approaches to understand the
workings of the human immune system in health and disease.
EXPERIMENTAL PROCEDURES
For details and associated references, see Extended Experimental
Procedures.
Fasting blood samples were drawn between 8 and 11 AM from healthy
volunteers on IRB-approved protocol (09-H-0239) and were processed within
30 min. PBMCs were cryopreserved or lysed and stored at 80C for subse-
quent RNA extraction using miRNeasy (QIAGEN) and hybridization to HG 1.0
ST arrays (Affymetrix).
Frozen PBMCs from all time points for a subject were stained for five panels
(Figure S1A) (Biancotto et al., 2011) using a common antibody mix on the same
day. Cell frequencies were expressed as percent of parent population.
Virus-neutralizing titers (A/California/07/2009 [H1N1pdm09], H1N1 A/Bris-
bane/59/07, H3N2 A/Uruguay/716/07, and B/Brisbane/60/2001) were deter-
mined according to Hancock et al. (2009). Reported titers were the highest
dilution that completely suppressed virus replication. Total and influenza-spe-
cific IgG/A frequencies of antibody-secreting cells were measured by ELISpot
assays modified for frozen samples (Ho et al., 2011).
Microarray data were processed using APT (Affymetrix). Batch effects were
removed using linear models in both raw and baseline-subtracted data. Fre-
quencies of cell populations were transformed by log10 (with zero values first
set to 0.01). Samples and populations with low viability or cell numbers,
respectively, were excluded.
Coherent changes from day 0 were computed using paired test in Limma
(Smyth, 2004). Surrogate variable analysis (Leek and Storey, 2007) was used
to remove hidden batch effects. The Wilcoxon test was used to compute
coherent changes in cell population frequencies. False discovery rates were
computed as described (Benjamini and Hochberg, 1995). Pathway enrichment
analyses were performed using the geneSetTest function (Limma) and path-
ways annotated by Ingenuity (http://www.ingenuity.com).
To assess inter- and intrasubject variation, we used data from days 7, 0,
and 70 for each parameter and fitted an ANOVA model to obtain: (1) total
R2, (2) the amount of variation explained by subject, and (3) the residual as
an estimate of intrasubject variation.
AdjMFC and MFC are defined in the text. To take the maximum of individual
viruses, we performed standardization by subtracting the median followed by
dividing the maximum absolute deviation (MAD) within each virus. To compute
adjMFC,webinned subjects basedon theirmaximumbaseline titers (across vi-
ruses) and then subtracted themedian and divided by theMADwithin each bin.
Contributions to titer response from age, gender, and ancestry were
assessed using ANOVA. Effects were then removed from the cell population
frequency and microarray data by retaining the residual after fitting a linear
model for eachprobe andsubset frequency.Cross-validation-basedpredictive
modelingwas done as described in the text andExtended Experimental Proce-
dures.Weuseddiagonal linear discriminant analysis for cell frequencydata and512 Cell 157, 499–513, April 10, 2014 ª2014 Elsevier Inc.when cell frequency and pathway status were combined. For transcript data
alone, we used partial least square (for data dimension reduction due to the
large number of genes) followed by linear discriminant analysis (PLS-LDA).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, five
figures, four tables, and a complete author list and can be found with this
article online at http://dx.doi.org/10.1016/j.cell.2014.03.031.
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